Showing 5511-5520 of 5643 results for "".
- Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertensionhttps://modernod.com/news/nicox-initiates-phase-2-study-of-ncx-470-in-open-angle-glaucoma-and-ocular-hypertension/2479962/Nicox announced the initiation of a phase 2 clinical study evaluating NCX 470, its novel, second-generation nitric oxide (NO)-donating prostaglandin analog, for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension by enrolling 10 patient
- Ocutech Introduces New Ves Falcon Autofocus Bioptic Telescopehttps://modernod.com/news/ocutech-introduces-new-ves-falcon-autofocus-bioptic-telescope/2479963/Following 6 years of development and testing, Ocutech has introduced its new VES Falcon Autofocus Bioptic Telescope, the company’s next generation autofocusing bioptic for the visually impaired. The Falcon is in initial limited release with select low-vision specialists in the United
- International Sports Vision Association Announces Appointment of Gary Esterow as Executive Directorhttps://modernod.com/news/international-sports-vision-association-announces-appointment-of-gary-esterow-as-executive-director/2479964/The International Sports Vision Association (ISVA), an organization of optometrists, athletic trainers, therapists, physicians and sports teams dedicated to evaluating, training, and improving vision performance in athletes, announced the appointment of Gary Esterow as Executive Director.
- ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-on-qr-110-for-lebers-congenital-amaurosis-10/2479967/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Thomas Burns, CEO of Glaukos, Joins Avedro’s Board of Directorshttps://modernod.com/news/thomas-burns-ceo-of-glaukos-joins-avedros-board-of-directors/2479974/Avedro announced that Thomas W. Burns has been elected to its board of directors. Mr. Burns has a proven track record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns is President, Chief Executive Officer and a mem
- Aussie Researchers Identify New Genetic Markers for Glaucomahttps://modernod.com/news/aussie-researchers-identify-new-genetic-markers-for-glaucoma/2479975/Australian researchers said they have identified 40 new genetic markers that increase a person’s risk of developing glaucoma, pointing to improvements in testing and predicting the risks of getting the eye disease, according to a
- Visual Function Problems May Be More Common in Children With Dyslexiahttps://modernod.com/news/visual-function-problems-may-be-more-common-in-children-with-dyslexia/2479977/Children with developmental dyslexia (DD) may be more likely to have visual deficits than their typically developing peers, a study suggests, according to a report in Reuters. Nearly 80% of the DD group had a deficit in at least one
- Data from BioTime’s OpRegen Program to Be Presented at AAO 2018https://modernod.com/news/data-from-biotimes-opregen-program-to-be-presented-at-aao-2018/2479983/BioTime announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27-30
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- A Daily Orange May Reduce AMD Risk, Study Findshttps://modernod.com/news/a-daily-orange-may-reduce-amd-risk-study-finds/2479986/People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with those who do not eat oranges, a study has found, according to a report in Medscape.